Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

October/November 2020 Vol 13, No 5 - FDA Approvals
Download PDF

On August 5, 2020, the FDA accelerated the approval of belantamab mafodotin-blmf (Blenrep; GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

The FDA granted belantamab mafodotin an orphan drug designation and a breakthrough therapy designation for this indication.

The FDA approved belantamab mafodotin based on the DREAMM-2 study, an open-label, multicenter clinical trial. Patients received belantamab mafodotin 2.5 mg/kg or 3.4 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity.

The efficacy end point included overall response rate (ORR) and response duration, as evaluated by an Independent Review Committee using the International Myeloma Working Group uniform response criteria. The ORR was 31% (97.5% confidence interval, 21%-43%). Overall, 73% of those who responded to therapy with the 2.5-mg/kg dose of belantamab mafodotin had a response lasting ≥6 months.

The most common (≥20%) adverse reactions to belantamab mafodotin therapy included keratopathy, decreased visual acuity, nausea, blurred vision, pyrexia, infusion-related reactions, and fatigue.

Because belantamab mafodotin is associated with a risk for serious ocular adverse events, including changes in the corneal epithelium resulting in severe vision loss and corneal ulcer, in addition to blurred vision and dry eyes, the drug is only available through a Risk Evaluation and Mitigation Strategy (REMS), the BLENREP REMS.

The recommended dose of belantamab mafodotin is 2.5 mg/kg as an intravenous infusion over approximately 30 minutes once every 3 weeks.

Related Items
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.